ArticlePloS one2020
Evaluation of the acceptability in France of the vaccine against papillomavirus (HPV) among middle and high school students and their parents.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review.Human vaccines & immunotherapeutics · 2021Pooled it
- Can physicians and schools mitigate social inequalities in human papillomavirus vaccine awareness, uptake and vaccination intention among adolescents? A cross-sectional study, France, 2021 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Trial
- Prevention is better than cure: Awareness and acceptance of the HPV vaccine for condyloma acuminata (CA) among college students who self-report no sexual experience.Human vaccines & immunotherapeutics · 2026Article
- Expanding vaccination competencies to community pharmacists: modelling the organizational and economic impacts of new human papilloma virus (HPV) vaccine pathways in France.BMC health services research · 2024Article
- A transversal cross-sectional study of factors related to HPV vaccination status and cancer screening participation among French women aged 25-40.BMC cancer · 2024Article
- A comprehensive narrative review of challenges and facilitators in the implementation of various HPV vaccination program worldwide.Cancer medicine · 2024Review
- Willingness of caregivers to have their daughters vaccinated against human papilloma virus and associated factors in Jimma Town, Southwest Ethiopia.Frontiers in global women's health · 2024Article
- Article
- Stages of HPV Vaccine Hesitancy Among Guardians of Female Secondary School Students in China.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2023Article
- "Human vaccines & immunotherapeutics · 2022Article
- Discrepancy of human papillomavirus vaccine uptake and intent between girls 9-14 and their mothers in a pilot region of Shanghai, China.Human vaccines & immunotherapeutics · 2022Article
- Acceptance and Willingness to Pay for Vaccine Against Human Papilloma Virus (HPV) Among Parents of Boys in Central Vietnam.Frontiers in public health · 2022Article
- Review
- Sexual behaviour, human papillomavirus and its vaccine: a qualitative study of adolescents and parents in Andalusia.BMC public health · 2021Article
- Article
- Article
- Parents' Intentions of Human Papillomavirus Vaccination for Students in Vietnam: A Cross-Sectional Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathogenic and oncogenic roles of papillomavirus (HPV) infections have been documented and shown to occur in women as well as in men. While other countries have already extended their vaccination guidelines to include boys, in 2019 the French National Authority for Health validated implementation of HPV vaccination in the 2020 vaccination schedule. There is, however, a climate of distrust in regard to vaccination in France, and there have been few studies to date regarding the acceptability of HPV vaccination in boys in France. The aim of this study was, therefore, to evaluate the acceptability of extending the recommendations for HPV vaccination in men, among middle and high school students and their parents.
methodsOur study (HPVac) was a prospective, multicenter, departmental, and descriptive survey applied to a sample of male middle and high school students attending schools in the Loire-Atlantique department and their parents. It took place from January 2017 to January 2018.
resultsWe analyzed the information obtained from 127 parent questionnaires and 145 children questionnaires. In terms of acceptability, 36.6% (n = 53) of the children and 37.8% (n = 48) of the parents were in favour of being vaccinated or of having their children vaccinated against HPV (51.7% (n = 75) and 50.4% (n = 64), respectively, were undecided). The perception of a risk stemming from HPV infection was positively associated with acceptability of the HPV vaccine. Being against vaccines in general, being discouraged by their parents, parents thinking that their child is not at risk, and the belief that the vaccine is not mandatory were arguments cited and significantly associated with a willingness to be vaccinated.
conclusionThis study revealed a lack of information among boys and their parents about HPV and its vaccination. It also clearly showed that taking time to discuss the consequences of an infection and the merits of being vaccinated can help parents overcome their reluctance. The children then generally go along with their parent's choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.